Table 2.
Allogeneic HSCT in MF/SS-CTCL
| Reference | N | Intervention | Efficacy | Transplant-related toxicities |
|---|---|---|---|---|
| Hosing et al55 | 47 | 6% ablative 94% RIC/NMA |
ORR = n/a, 2-year PFS 40%, 2-year OS 67% 4-year PFS 26%, 4-year OS 51% |
1-year NRM 10% 2-year NRM 17% Gr 2–4 aGVHD 40%; cGVHD 28% |
| Duarte et al56 | 60 | 33% ablative 67% RIC/NMA |
ORR = n/a, 2-year PFS 34%, 2-year OS 54% 5-year PFS 32%, 5-year OS 46% 7-year PFS 30%, 7-year OS 44% |
1-year NRM 20% 7-year NRM 22% |
| Paralkar et al57 | 12 | 17% ablative 83% RIC |
ORR = 67%, 2-year PFS 23%, 2-year OS 56% | 1-year NRM 25% |
| De Masson et al58 | 37 | 32% ablative 68% RIC/NMA |
ORR = n/a, 2-year PFS 31%, 2-year OS 57% | 1-year NRM 18% 2-year NRM 18% Gr 2-4 aGVHD 76%; cGVHD 44% |
| Lechowicz et al59 |
129 | 36% ablative 64% RIC/NMA |
ORR = n/a, 1-year PFS 31%, 1-year OS 54% 5-year PFS 17%, 5-year OS 32% |
1-year NRM 19% 5-year NRM 22% Gr 2-4 aGVHD 41%; cGVHD 43% |
| Isufi et al60 | 16 (n = 23; 16 MF/SS; 7 G/D TCL) | RIC except 2 haploidentical | CR rate = 56% OS 75% (12 of 16 patients) w/median follow-up 5.5 years |
100-day NRM 12% Gr 2-4 aGVHD 50%; cGVHD 56% |
| Weng et al61 | 35 | 100% NMA | ORR (CR) = 80% (57%), 2-year PFS 60%, 2-year OS 68% 5-year PFS 41%, 3-year OS 62%, 5-year OS 56% |
1-year NRM 3% 2-year NRM 14% Gr 2-4 aGVHD 16%; cGVHD 32% |
aGVHD, acute GVHD; cGVHD, chronic GVHD; Gr, grade; NMA, non-myeloablative; RIC, reduced-intensity conditioning.